What is Genome?
Genome & Company is a publicly traded (KRX: 314130) clinical-stage biotechnology firm headquartered in Seongnam, Republic of Korea. The company is dedicated to the discovery and development of novel therapeutics within the immuno-oncology space. Its diverse pipeline leverages modalities such as microbiome-based treatments, novel target immune checkpoint inhibitors, and fusion proteins, aiming to address critical unmet needs for cancer patients. This strategic focus positions Genome at the forefront of advanced cancer treatment research.
How much funding has Genome raised?
Genome has raised a total of $29.5M across 2 funding rounds:
Series A
$3M
Series B
$26.5M
Series A (2020): $3M with participation from DongKoo Bio& Pharma
Series B (2020): $26.5M led by Genome & Company
Key Investors in Genome
Genome & Company
Genome & Company is the company itself, indicating internal investment or a specific corporate funding initiative within this round.
DongKoo Bio& Pharma
DongKoo Bio& Pharma is a pharmaceutical company, likely investing to gain access to Genome's innovative immuno-oncology pipeline and therapeutic modalities.
Undisclosed investor
An undisclosed investor participated in this funding round, suggesting a strategic interest in Genome's biotechnology advancements.
What's next for Genome?
With a substantial enterprise-level funding round and a recent strategic investment, Genome is poised for accelerated growth and development. The capital infusion is expected to fuel the advancement of its immuno-oncology pipeline, potentially enabling further clinical trials and the expansion of its research capabilities. The company's commitment to innovative therapeutic modalities suggests a forward-looking strategy focused on capturing significant market share in the rapidly evolving oncology sector. Future developments will likely center on clinical trial outcomes and strategic partnerships to bring its novel treatments to patients.
See full Genome company page
